Onabotulinum May Decrease Opioid Use, Reduce Severity and Frequency of Nonmigraine Headache
In patients with chronic nonmigraine headaches, onabotulinum toxin type A injections may reduce pain severity and frequency of headaches.
Treatments
First Generic Versions of Fingolimod Gain FDA Approval
The FDA has approved the first generic versions of fingolimod for the treatment of relapsing forms of multiple sclerosis in adults.
Trial Results Indicate Potential for Celecoxib in the Acute Treatment of Migraine Pain
An oral solution of celecoxib, a selective inhibitor of cyclo-oxygenase 2, is superior to placebo for the acute treatment of migraine pain.
Fast Acting Treatment for OFF Episodes in Parkinson Disease Resubmitted
Sunovion has resubmitted the NDA for apomorphine sublingual film for the treatment of OFF episodes experienced by patients with Parkinson disease.
Risdiplam Gets Priority Review for Spinal Muscular Atrophy
Recently announced results from part 2 of the SUNFISH trial, which evaluated the safety and efficacy of risdiplam in patients with type 2 or 3 SMA aged 2 to 25 years, showed that the treatment met its primary end point.
Cenobamate Gains FDA Approval for Partial-Onset Seizures
Although its exact mechanism in the treatment of partial-onset seizures is unknown, cenobamate has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents.
Risdiplam for Spinal Muscular Atrophy Meets Primary End Point in Motor Function
Positive data announced from the pivotal part 2 of the SUNFISH trial that evaluated the safety and efficacy of risdiplam in adult and pediatric patients with Type 2 or Type 3 SMA.
Endovascular Therapy vs Thrombolysis for Stroke With Large Vessel Occlusion and Mild Symptoms
In patients with mild neurologic deficiency secondary to acute ischemic stroke with large vessel occlusion, functional outcomes were comparable following endovascular therapy or intravenous thrombolysis.
ECT Effectively Reduced Agitation, Improved Functioning in Dementia
Researchers found ECT was a safe for patients with dementia experiencing agitation or aggression, as well as for those with comorbid medical conditions.
Diroximel Fumarate Approved for Relapsing Forms of Multiple Sclerosis
Vumerity (diroximel fumarate; Biogen) has been approved for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Next post in Multiple Sclerosis
